Dr. William Edmund Cooke and the Naming of Asbestosis: How a 1924 Autopsy Created Medicine's Asbestos Reckoning

In 1924, a Lancashire hospital pathologist autopsied a 33-year-old asbestos textile worker named Nellie Kershaw and published the first detailed medical case report linking pulmonary fibrosis to asbestos inhalation. Three years later, on December 3, 1927, the same pathologist — Dr. William Edmund Cooke — published a follow-up paper in the British Medical Journal that coined the disease's name: "pulmonary asbestosis."^[1] Those two papers, written by a working pathologist who never received a knighthood or a London chair, fix the date on which the world's asbestos manufacturers were put on constructive notice that their product killed workers. A century later, every modern U.S. asbestos lawsuit reaches back to the timeline Cooke established.

Who was Dr. William Edmund Cooke?

William Edmund Cooke, MD, was a hospital pathologist and bacteriologist in the industrial Lancashire of the 1920s. His professional life was based at two institutions in northwest England — Wigan Infirmary and Leigh Infirmary — and his clinical work was the kind of unglamorous, day-to-day pathology that most history forgets: cause-of-death determinations, tissue analyses for ordinary inquests, microscope work in rooms above hospital wards. He was not a knighted Harley Street consultant. He was not a London professor. He was the pathologist on call when a 33-year-old asbestos textile worker named Nellie Kershaw died of progressive lung disease in 1924. A coroner needed someone competent to determine the cause.

That ordinary professional context is what makes Cooke's role in asbestos history so consequential. He was close to the work — close to the mill towns where asbestos was processed, close to the funeral homes where its victims arrived, close to the inquest rooms where families demanded answers. He was also methodical enough to write his findings up, careful enough to send them to the British Medical Journal. Persistent enough to publish twice — once in 1924 with the first case report, and again in 1927 with a fuller statement.^[2]

Beyond his asbestos papers, biographical detail on Cooke is thin in the modern medical-history literature. He does not appear in the major medical biographies of his era. The British medical establishment of the 1920s — dominated by London professors and Oxbridge-trained physicians — gave him no particular professional honors. He is remembered today for two papers in the BMJ. That is enough.

What happened in 1924? The Nellie Kershaw case

Nellie Kershaw was a textile worker who began working with asbestos in her early teens. By 1922 she was too ill to continue, and by 1924 she was dying. Her family physician identified the cause of her decline as occupational exposure to asbestos dust, and after her death Cooke was assigned to perform the autopsy.^[2]

What Cooke found inside her lungs was unusual and, to him, immediately significant: extensive fibrotic scarring distributed in a pattern that did not match any of the recognized mineral dust diseases of the era. Coal worker's pneumoconiosis presented differently. Silicosis — already well documented in stone-cutters and miners — produced different lesions. The fibrosis in Kershaw's lungs followed a distribution that pointed at a specific occupational exposure: the asbestos textile fibers she had spent fifteen years inhaling.

Cooke published the case in the British Medical Journal that same year, in a paper that documented the exposure history, the clinical course. The post-mortem pathology in sufficient detail that the case could be replicated, debated, and built upon by other pathologists. The paper did not give the disease a name. It described the disease and identified asbestos as the cause. That, on its own, was historically significant — but it was also assimilable into the existing medical category of "pulmonary fibrosis due to dust." Without a distinct name, the case risked being filed away as one more entry in a long catalog.

"The medical history that matters to our clients isn't abstract. The dates Cooke published — 1924 and 1927 — are the dates the asbestos industry stopped being able to plausibly claim it didn't know. Every internal Johns-Manville document we read in discovery, every Owens-Corning memo from the 1930s and 1940s, sits inside a timeline that began with a pathologist in Wigan writing up an autopsy."

— David Foster, Senior Mesothelioma Advocate, Danziger & De Llano

What happened in 1927? Cooke names the disease

Three years after the Kershaw paper, on December 3, 1927, Cooke published a fuller paper in the British Medical Journal titled simply "Pulmonary Asbestosis" — the first published use of that specific clinical term.^[1] The 1927 paper presented a second case in addition to Kershaw's, described the characteristic pathological findings in greater detail. Most importantly, gave the disease a name.

In the same December 3, 1927 issue of the BMJ, two companion papers appeared on the consecutive pages immediately following Cooke's:

• S. McDonald, "Histology of Pulmonary Asbestosis," BMJ 2(3491):1025–1026 — providing the microscopic pathology that supported Cooke's clinical and gross pathology findings
• Sir Thomas Oliver, "Clinical Aspects of Pulmonary Asbestosis," BMJ 2(3491):1026–1027 — describing what the disease looked like in living patients, from one of the most authoritative voices in British industrial medicine

The clustering was unusual. Three independent papers on a single occupational disease, by three different authors, appearing on consecutive pages of the same issue, was not the way the BMJ ordinarily worked. The arrangement signaled coordination among the British medical leadership — the BMA's annual meeting had been held in Edinburgh that July. Asbestos disease had clearly been discussed there in some form, with the formal written-up papers appearing in print in December.^[2]

In his 1927 paper, Cooke also described what he called "curious bodies" in the lung tissue — golden-yellow, drumstick-shaped structures visible under the microscope, coated with what appeared to be iron-containing protein. He did not yet know what they were, exactly. Later pathologists would identify them definitively as asbestos fibers that had been coated by macrophages — the body's defensive cells trying. Failing, to wall off particles too large to remove. They are now universally known as "asbestos bodies" or "ferruginous bodies," and their density in lung tissue remains a quantitative marker for cumulative asbestos exposure in modern pathology and in the Helsinki Criteria for diagnosing asbestos-related disease.^[4]

Why did naming the disease change the conversation?

Before 1927, asbestos disease existed in the medical literature only as scattered case reports of "fibrosis" or "dust disease" — terms that placed the condition inside larger, vaguer categories. Treating physicians could see the cases as one-offs. Manufacturers could dismiss them as unrelated to their products. Regulators could pass over them as anecdotes.

Once the disease had a name — "pulmonary asbestosis" — it became a discrete category. Clinicians could diagnose it. Pathologists could confirm it. Inspectors could investigate it. Insurers could classify it. Lawyers could plead it. The naming did not change the biology; the disease had been killing workers for decades before Cooke published. But the naming changed the social and institutional infrastructure around the disease. Asbestosis became a fact in the world.

The chest specialist W. Burton Wood admitted as late as 1929 that "I have failed to find any mention of asbestos in standard works on pulmonary disease." By the early 1930s, that was no longer true. Cooke's name for the disease was the wedge that opened the textbooks.^[2]

How did Cooke's papers change British policy?

The institutional response in the United Kingdom moved quickly. Within months of the December 1927 publications, the British Home Office and Factory Inspectorate were under pressure to act:

February 1928 — Glasgow case. Dr. MacGregor, the Medical Officer of Health for Glasgow, formally drew the Factory Inspectorate's attention to an asbestos worker with pulmonary fibrosis. This was the first time a public health official had explicitly invoked the new diagnostic category against the asbestos industry.^[2]

March 1928 — Walter Leadbetter inquest. A 34-year-old asbestos worker employed by J.W. Roberts Ltd. in Armley, Leeds, died of asbestos-related lung disease. At the inquest, the workers' GP — Dr. Ian Grieve, whose 1927 Edinburgh MD thesis had documented that nearly every J.W. Roberts worker developed respiratory disease within five years — testified about the pathology. Despite aggressive cross-examination by counsel for Turner & Newall (J.W. Roberts's parent company), the jury returned a verdict of "broncho-pneumonia and fibrosis of lungs due to asbestos dust." HM Medical Inspector of Factories attended in person.^[2]

1928 — official investigation commissioned. The Chief Inspector of Factories' annual report for 1928 explicitly credited the recent medical publications, including Cooke's, with reviving official interest in asbestos. The Home Office commissioned what became the Merewether and Price investigation — a systematic survey of asbestos workers in British factories conducted by E.R.A. Merewether (a Factory Inspectorate medical officer) and C.W. Price.^[2]

1930 — Merewether and Price report. The investigation found pulmonary fibrosis in roughly a quarter of the workers examined and confirmed that the disease was a function of dust exposure intensity and duration. The report's recommendations formed the technical basis for new workplace standards.

1931 — UK Asbestos Industry Regulations. The world's first national asbestos workplace regulations took effect, mandating dust suppression, ventilation, and other controls in asbestos factories. The arc from Cooke's 1924 case report to enforceable national regulation took seven years.

How did the United States respond?

The U.S. medical response to Cooke was immediate. On January 14, 1928 — six weeks after the December 1927 BMJ papers — the Journal of the American Medical Association ran an editorial directly citing Cooke's 1927 case and urging:^[2]

"Nevertheless, asbestosis, because of its dangers and its unique pathologic features, deserves more attention than it has had."

— JAMA, editorial, January 14, 1928

Subsequent U.S. medical publications followed across the late 1920s and 1930s, and by the mid-1930s asbestosis was an established occupational disease category in American industrial medicine. Worker compensation cases for asbestosis began to be litigated in U.S. courts in the same decade. The industry's internal records, disclosed in decades of subsequent civil discovery, show that the major U.S. asbestos producers — including Johns-Manville and Raybestos-Manhattan — were monitoring the medical literature carefully and discussing it internally throughout the 1930s.^[9]

The U.S. regulatory response, however, lagged the medical knowledge by roughly four decades. OSHA's first asbestos standard at 29 CFR 1910.1001 was not issued until 1972 — forty-five years after Cooke named the disease.^[5] That regulatory gap, against medical knowledge that was well established by the late 1920s, is the historical foundation of every modern U.S. asbestos lawsuit.

Why does Cooke's 1924–1927 date matter to litigation today?

Modern asbestos litigation routinely turns on what manufacturers knew and when. Plaintiffs argue that the manufacturers of asbestos-containing pipe insulation, gaskets, refractories, brake linings, textiles. Cement pipe were on notice of the disease risk for decades before they warned workers or revised their products. Defense counsel try to push that notice date as late as possible. The 1924–1927 publications by Cooke and the British medical establishment are an anchor on the plaintiff side of that argument that no defense lawyer has ever been able to dislodge.^[9]

The reasoning is straightforward. By the late 1920s:

• A British pathologist had documented and named the disease in two BMJ papers
• The British Medical Association had effectively endorsed the diagnosis via the coordinated December 1927 BMJ cluster
• JAMA had editorialized on the disease in the United States within six weeks of Cooke's naming paper
• British government inquests had returned verdicts of death from asbestos dust
• The British government had commissioned an investigation that would lead to national regulation

Against that record, the U.S. asbestos industry's claim to have been ignorant of the disease risk into the 1950s, 1960s, and 1970s — when it was first sued — is not credible to most juries. The industry's internal documents from the 1930s onwards, disclosed in U.S. discovery, repeatedly show executives discussing the medical literature, debating how to respond, and most damningly, deciding not to warn workers. D&D's review of the industry-knowledge timeline sets out the documentary evidence in detail.

What is the difference between asbestosis and mesothelioma?

Cooke named asbestosis. He did not name mesothelioma. The two diseases are linked by their common cause — asbestos exposure — but they are biologically distinct and were recognized at different times in medical history.

Asbestosis is a non-cancerous, progressive scarring (fibrosis) of the lung parenchyma. It develops in workers with cumulative asbestos exposure heavy enough to overwhelm the lung's clearance mechanisms. The fibrosis is bilateral, basal, and progressive; once present, it does not reverse, and it continues to worsen even after exposure ends. Severe asbestosis impairs gas exchange and ultimately produces respiratory failure. The Cooke 1924–1927 papers established asbestosis as a medical reality.^[4]

Mesothelioma is a cancer of the mesothelial cells lining the pleura (chest cavity), peritoneum (abdomen), pericardium (around the heart), or tunica vaginalis (around the testis). It is caused by asbestos exposure but is biologically distinct from asbestosis — different cells, different progression, different prognosis. The asbestos–mesothelioma cancer link was not firmly established in the medical literature until J.C. Wagner's 1960 South African crocidolite-mining cohort and Irving Selikoff's 1964 New York insulator cohort. Both papers built on Cooke's foundational work but identified an additional, more aggressive disease in the same exposure population.^[4]

Workers exposed to asbestos can develop both diseases. Many mesothelioma patients also show asbestosis on chest imaging; many asbestosis patients live long enough to develop mesothelioma decades later. Modern medical practice treats them as overlapping endpoints of the same exposure, and modern legal practice treats them as compensable through the same trust-fund and litigation systems.

How is asbestosis compensated today?

Asbestosis is compensable through the same legal infrastructure that handles mesothelioma and asbestos-related lung cancer cases. The three primary streams are:

1. Asbestos bankruptcy trust funds. Approximately 60 asbestos manufacturers established Section 524(g) bankruptcy trusts that continue to pay claims today, holding more than $30 billion in remaining assets. Asbestosis claimants file alongside mesothelioma and lung cancer claimants. The trust system pays asbestosis at scheduled rates tied to disease severity (typically graded on pulmonary function tests and imaging findings).^[8]

2. Personal injury lawsuits against solvent manufacturers. Where a solvent defendant remains in the chain of products, asbestosis claims can be filed against that manufacturer on the same theories — failure to warn, design defect, negligence — that govern mesothelioma claims. An experienced asbestos firm can identify viable defendants and evaluate likely recovery.

3. VA disability for service-connected veterans. The VA recognizes asbestosis as a service-connected hazardous-material disease for veterans whose first asbestos exposure occurred during military service — typically Navy, Coast Guard, or Marine Corps service aboard ships, in shipyards, or in vehicle maintenance shops before the 1980s. Asbestosis is rated by pulmonary function impairment under the VA's respiratory schedule. Veterans with asbestosis can receive monthly VA disability payments without offsetting any civilian trust or lawsuit recovery.

Diagnostic confirmation typically requires chest imaging (high-resolution CT is the modern standard), pulmonary function testing. An occupational history sufficient to support causation under the Helsinki Criteria or a comparable medical-legal standard. Pathological confirmation through lung biopsy is occasionally pursued but is not usually necessary in cases with clear exposure and imaging.

Frequently asked questions about asbestosis and the Cooke history

Cooke's 1924 and 1927 BMJ papers established asbestosis as a named, recognized occupational disease — the foundation on which a century of subsequent medical, regulatory. Legal development has been built. The questions answered above and in the FAQ block below are the ones modern asbestosis and mesothelioma clients and their families ask most often. The historical record is unusually clear: medical knowledge was in place by the late 1920s, and corporate notice of that knowledge is well documented in industry archives.

Talk to a mesothelioma and asbestosis attorney

Danziger & De Llano represents workers and their families diagnosed with asbestosis, mesothelioma, and asbestos-related lung cancer across all 50 states. The firm's exposure-history work is grounded in the same documentary record that begins with Cooke's 1924 autopsy of Nellie Kershaw — every internal corporate document, every regulatory filing, every state-of-the-art medical study from the 1920s forward forms part of the historical chain that supports modern asbestos claims. If you or a loved one has been diagnosed with asbestosis or mesothelioma, contact us for a free consultation. Call (855) 699-5441 or take our free case assessment.

Our team will review the exposure history, identify potential defendants, file all applicable asbestos trust fund claims, evaluate VA eligibility for service-connected veterans, and prosecute lawsuits where solvent defendants remain. There is no fee unless we recover compensation. Statutes of limitations are short — typically one to three years from diagnosis — so prompt consultation preserves every option.